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ABSTRACT
Background: Undernutrition is associated with an elevated risk
of mortality among children in low- and middle-income coun-
tries. Small-quantity lipid-based nutrient supplements (LNS) have
been evaluated as a method to prevent undernutrition and
improve infant development, but the effects on mortality are
unknown.
Objective: Our objective was to evaluate the effect of LNS on all-
cause mortality among children 6–24 mo old.
Methods: We conducted a systematic review and meta-analysis
of randomized controlled trials of LNS designed to prevent
undernutrition, with or without other interventions. Literature
was searched in May 2019 and trials were included if they
enrolled children between 6 and 24 mo old and the period of
supplementation lasted ≥6 mo. We extracted data from partici-
pant flow diagrams and contacted study investigators to request
data. We conducted a meta-analysis to produce summary RR
estimates.
Results: We identified 18 trials conducted in 11 countries that
enrolled 41,280 children and reported 586 deaths. The risk of
mortality was lower in the LNS arms than in the non-LNS
comparison arms (RR: 0.73; 95% CI: 0.59, 0.89; 13 trials).
Estimates were similar when trials with maternal LNS intervention
arms were added or when alternative formulations of LNS were
excluded. The results appeared stronger in trials in which LNS
were compared with passive control arms. Excluding these contrasts
and only comparing multicomponent arms with LNS groups
and comparison groups that contained all the same components
without LNS attenuated the effect estimate (RR: 0.82; 95% CI:
0.61, 1.10).
Conclusions:LNS provided for the prevention of undernutritionmay
reduce the risk of mortality, but more trials with appropriate compar-
ison groups allowing isolation of the effect of LNS alone are needed.
This study was registered at www.crd.york.ac.uk/PROSPERO
as CRD42019128718. Am J Clin Nutr 2020;111:207–218.
Keywords: lipid-based nutrient supplement, complementary feed-
ing, child mortality, infants and young children, home fortification
Introduction
Globally, an estimated 5.5 million children <5 y of age
die each year, the majority from preventable causes (1).
Undernutrition among infants and children <2 y of age
remains common in low- and middle-income countries and is
associated with increased risk of mortality, including among
children with mild to moderate degrees of undernutrition (2, 3).
Among severely or moderately malnourished children, ready-
to-use therapeutic and supplementary foods have been found
to significantly improve recovery rates and reduce the risk of
mortality (4, 5). Lipid-based nutrient supplements (LNS) are
available in various quantities and formulations for the prevention
or treatment of malnutrition (6) and are designed to provide
multiple micronutrients embedded in a food base that also
provides energy, protein, and essential fatty acids. Large-quantity
LNS are typically used for treatment of severe acute malnutrition
and provided in dosages of ≥500 kcal/d (5). Medium-quantity
LNS are generally offered as ready-to-use supplementary food
for the treatment of moderate acute malnutrition in dosages of
250–500 kcal/d, and small-quantity LNS are generally given as
100–120 kcal/d for the prevention of undernutrition.
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The primary objective of most trials of small-quantity and
some trials of medium-quantity LNS has been to evaluate their
efficacy for the prevention of malnutrition, and such trials have
therefore focused on linear growth and risk of stunting as their
primary outcome measures. Many trials also have evaluated
indicators of child development as secondary outcomes. The
combination of macro- and micronutrients addresses multiple
potential nutritional deficiencies and thus may also reduce child
mortality, although none of the trials had been designed with this
as an explicit objective. A recently published review considered
the impact of small-quantity LNS on a variety of outcomes,
including all-cause mortality (7). However, the analysis of the
effect on mortality was limited because the authors only included
3 trials, 2 of which reported deaths when children were <6 mo
old and therefore too young to have been directly exposed to
LNS. The recent publication of a number of additional large trials
of LNS provides a larger sample size to examine this outcome.
Thus, the objective for this meta-analysis is to evaluate the effect
of small- and medium-quantity LNS on child mortality, using an
expanded set of trials and restricting the analysis to children who
were ≥6 mo old, i.e., eligible to receive LNS. We hypothesize
that children 6–24 mo old who receive LNS for a minimum of 6
mo will have a lower mortality rate than those who do not receive
LNS.
Methods
The study was registered through Prospero (CRD42019
128718) and a detailed statistical analysis plan was developed
and posted publicly (https://osf.io/q76r8/) before beginning the
analysis. The primary and only outcome considered in this
analysis was all-cause mortality.
Potential trials for inclusion in the meta-analysis were identi-
fied using a systematic review process that mirrored that of the
recent meta-analysis of LNS (7). To capture additional, recently
published trials, we repeated the search protocol described by
Das et al. (7) Specifically, we searched 16 international and
9 regional databases in May 2019 using the keyword and the
same controlled vocabulary search terms laid out by Das et al.;
reference lists of newly included trials were reviewed to identify
any additional trials. The titles and abstracts of all identified
records were screened; full-text reports for potentially eligible
trials were reviewed using the inclusion and exclusion criteria
described below. When only meeting abstracts were identified,
we contacted the authors to invite them to share their results.
Inclusion and exclusion criteria
We restricted this analysis to prospective randomized con-
trolled trials conducted in low- or middle-income countries that
were designed such that all enrolled children were eligible to
receive ≥6 mo of supplementation between 6 and 24 mo of age.
Trials were excluded if they focused primarily on the treatment,
not prevention, of malnutrition. Generally, this was defined as
those trials in which severe or moderate malnutrition was an
inclusion criterion for children in the trial. We did not include
trials that provided ≥500 kcal LNS/d because such quantities
exceed the average energy needed from non-breast-milk sources
at 6–12mo (6) and thusmay reduce breast-milk intake and/or lead
to incomplete consumption of the daily ration, thereby reducing
the dose of micronutrients and fatty acids received. Both of
these consequences could compromise the potential benefits of
LNS. Trials that did not formally exclude children with severe or
moderate acute malnutrition, as part of the larger sample, were
included in this analysis.
Because many trials enrolled children before the supplemen-
tation age of ≥6 mo, we restricted our analysis to children
who were still in the trial at the time of initiation of child
supplementation. When possible, this restriction was applied
through careful extraction of data from publications; when not
possible, we reached out directly to investigators.
Our primary comparison was of children in small- and
medium-quantity LNS intervention groups with those in non-
LNS control groups. If a single trial contained multiple relevant
LNS interventions (e.g., varying dosages, formulations, or
combinations in different arms), we combined these groups so
that there was a single comparison per trial. In some cases,
LNS were provided in combination with other interventions
within a single intervention arm. All forms of small-quantity
and medium-quantity LNS and interventions that included
LNS were included as “LNS” in the primary analyses and
were differentiated in prespecified sensitivity analyses described
below. Non-LNS comparison groups varied by trial. For the
primary comparison, we considered all non-LNS arms as a
“Control” group for that trial, excluding intervention arms
that received other types of (non-LNS) child supplementation,
such as micronutrient powder or other fortified blended
foods.
Intervention arms that included maternal LNS supplemen-
tation, in addition to child LNS, were excluded from the
primary analysis. Maternal LNS supplementation may influence
infant mortality independently of child LNS supplementation, as
suggested by the lower RR for neonatal mortality in a recent
meta-analysis of maternal LNS trials (0.72; 95% CI: 0.47, 1.10)
(8). Although this was not statistically significant, that analysis
was limited in power owing to a relatively small sample size,
because only 3 trials were included (8). Our meta-analysis
focuses on child mortality after 6 mo of age, when a residual
effect of maternal supplementation is less likely. Nonetheless,
it is possible that maternal LNS supplementation may affect the
risk of mortality after 6 mo, e.g., because of longer-term effects
on immune function related to birth size (9). For this reason, we
excluded the trials that included maternal LNS from our primary
analysis, but included them in a separate sensitivity analysis
described below.
Risk of bias assessment
Risk of bias in the included trials was assessed using the
criteria in the Cochrane Handbook for Systematic Reviews of
Interventions (10). Two reviewers evaluated each trial against
the following criteria: random sequence generation, allocation
concealment, blinding of participants and personnel, outcome
assessment bias, incomplete outcome assessments, selective
outcome reporting, and other sources of bias.
Data extraction
Data were extracted primarily from participant flow diagrams.
When insufficient detail was available in the diagram, we
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contacted investigators for additional information. If the child
supplementation began at enrollment, our denominator for
analysis was the number of children enrolled. All deaths after
enrollment were considered events. If supplementation began
after enrollment (e.g., trials that enrolled during pregnancy),
the denominator was the number of children alive and still
enrolled when supplementation began. Only deaths that occurred
after supplementation began were considered as events. Data
extraction was independently replicated.
Data analysis
Our parameter of interest was the pooled RR of all-cause child
mortality comparing LNS with non-LNS intervention groups.
We used a patient-weighted random-effects method proposed by
Shuster and Walker (11, 12) to include trials in which 1 or both
arms had 0 events.We did not adjust ourmethods for the inclusion
of cluster-randomized trials. A recent meta-epidemiological
study comparing effect estimates between cluster-randomized
trials and individually randomized trials found no systematic
differences between the estimation methods and concluded that
the 2 types of trials can be safely pooled together for binary
outcome meta-analyses (13). Statistical analyses were performed
using SAS software, version 9.4 (SAS Institute Inc.).
We explored trial protocol heterogeneity by summarizing the
methods, participants, interventions, monitoring approaches, and
potential for bias of each trial. Trials with protocols that differed
substantially from the rest triggered discussion of sensitivity
analyses, which are described below. For statistical heterogeneity
we present I2 and τ 2 statistics.
Based on a preliminary literature search, we expected to find
≥18 trials with ≥32,500 participants and 400 deaths. Assuming
similarly sized trials with equal-sized treatment groups, wewould
expect to have 80% statistical power to detect an RR of 0.77
between intervention and control groups at the 95% confidence
level.
Sensitivity and secondary analyses
The majority of trials used similar LNS distribution mech-
anisms [e.g., weekly or monthly rations provided by study
staff, community health workers, or other health extension
agents together with some infant and young child feeding
(IYCF) counseling] and used similar formulations of LNS,
specifically peanut- and milk-based products providing ∼1 RDA
of most micronutrients. However, some trials integrated LNS
supplementation together with other types of interventions, such
as water, sanitation, and hygiene (WASH) or enhanced morbidity
monitoring and treatment. The comparison groups also differed
between trials. Most had an active control group for which
there was a similar visit frequency or set of activities as for
the LNS intervention group. However, some trials had a passive
control group or nonintervention group, for which there were no
contacts between study staff and research participants apart from
enrollment and follow-up data collection visits. In addition, some
trials provided alternative LNS formulations or supplementation
to both the mother and child. These variations in trial design
might affect the effect size of the mortality estimates. Therefore,
we conducted a series of sensitivity analyses using the following
inclusion and exclusion criteria applied to the data included in the
primary analysis:
1) Inclusion of intervention arms with maternal supplement
components.
2) Exclusion of intervention arms with LNS formulations that
were not milk- and peanut-based.
3) Separate comparison of multicomponent arms with LNS
groups and comparison groups that contained all the same
components without LNS (e.g., LNS + WASH compared
with WASH) and exclusion of trials with only passive
control arms.
Finally, in a secondary analysis, we conducted a comparison
of LNS intervention arms with non-LNS supplementation arms.
Some trials included products such as micronutrient-fortified
wheat–soy blend (WSB), corn–soy blend (CSB), Nutritabs, or
micronutrient powders (MNPs). All of these analyses were
considered exploratory.
Results
We identified 18 trials that met the inclusion criteria for the
primary, secondary, or sensitivity analyses (Figure 1). The 18
included trials were conducted in 11 countries, enrolling 41,280
children and recording 586 deaths (14–32). A brief description
of each trial is included in Table 1 and information about how
each trial was included in each set of analyses is shown in
Supplemental Table 1. Trials were considered to generally have
a low risk of bias, with the exception of blinding of participants
owing to the nature of the intervention (Supplemental Table 2
and Supplemental Figure 1).
In the primary analysis, which included 13 trials with 34,051
participants, there was a 27% lower risk of all-cause mortality
(RR: 0.73; 95% CI: 0.59, 0.89; I2 = 23.2%, τ 2 = 0.044)
(Figure 2). All but 2 of the trials had RR point estimates <1;
however, only 1 trial was independently statistically significant
(iLiNS-Zinc in Burkina Faso). The point estimate of the RR
did not differ in sensitivity analyses in which maternal LNS
intervention arms were added (Figure 3; 15 trials; 39,903
participants) or when only peanut + milk-based formulations
of LNS intervention were included (Figure 4; 12 trials; 30,776
participants).
In a sensitivity analysis in which passive control trials were
excluded and multicomponent arms (e.g., WASH + Nutrition)
were compared with reference groups with the same components
without LNS, the point estimate of the RR shifted toward
the null and was no longer statistically significant (0.82; 95%
CI: 0.61, 1.10; I2 = 33.3%, τ 2 = 0.10) (Figure 5; 11 trials;
23,373 participants). To understand this attenuation of the point
estimate, we further examined whether the Water, Sanitation,
or Handwashing interventions might have had an effect on
mortality (Supplemental Table 3). In the Kenya trial, the
WASH + Nutrition group had the lowest risk of death (10/1000),
followed by the Active Control group (16/1000) and the Water
group (19/1000). The Nutrition-only arm had a mortality rate of
24/1000 and all other groups were between 20/1000 and 30/1000.
None of the Water, Sanitation, Handwashing, or combined
WASH arms had a mortality rate lower than the Active Control
arm, even though all arms except for the passive control arm had
active visitation. For comparison, inWASHBenefits Bangladesh,
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2107 records identified through
database searching
1407 records after duplicates
removed
1466 records screened
1349 excluded on the
basis of title and
abstract
17 duplicate records
already included in Das
et al. (7)
100 full text reports assessed for
eligibility
17 trials (54 reports)
included in the Cochrane
review
5 ongoing trials
16 trials (76 reports)
included in the review
2 ongoing trials with
data included in the
review (1 report)
9 trials (11 reports)
excluded: non RCT,
non LNS, malnutrition
7 ongoing trials (9
reports) excluded: no
data
3 systematic reviews
excluded
Das et al. (7)
13 trials included
in primary analysis
(LNS vs. control)
10 –15 trials
included in
sensitivity analyses
7 trials included in
secondary analysis
(LNS vs. non LNS)
FIGURE 1 Study flow diagram. LNS, lipid-based nutrient supplement; RCT, randomized controlled trial.
none of the Water, Sanitation, or Handwashing arms, or the
combined WASH or WASH + Nutrition arms, had a mortality
rate lower than the control group (in this case, passive control);
the only arm that had lower mortality was Nutrition (only). In the
other WASH + Nutrition trial (the SHINE trial in Zimbabwe),
the mortality rate was also lowest in the IYCF arm and was not
improved by the addition of WASH.
In a secondary analysis, we compared LNS interventions with
other supplement comparison groups (non-LNS, e.g., WSB++,
CSB, MNP, or Nutritabs). The results were not statistically
significant (RR: 0.76; 95% CI: 0.37, 1.58), but the point estimate
was similar to that of the primary analysis (Supplemental
Figure 2; 7 trials; 8681 participants). There was a much smaller
sample size and larger degree of heterogeneity in these analyses,
however (I2 = 52.8%, τ 2 = 0.384).
Discussion
These results suggest that LNS supplementation for a mini-
mum of 6 mo among children aged 6–24 mo may reduce the
risk of mortality. The estimated reduction of 27% in all-cause
mortality between 6 and 24 mo of age in the primary analysis,
based on data from 13 trials with 34,051 children, was robust
to the inclusion of interventions combined with maternal LNS
supplementation or to the exclusion of alternative formulations of
LNS. Our primary analysis included all studies and intervention
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/111/1/207/5613093 by Tam
pere university library user on 07 February 2020
Meta-analysis of effect of LNS on child mortality 211
T
A
B
L
E
1
D
es
cr
ip
tio
n
of
ea
ch
tr
ia
li
nc
lu
de
d
in
th
e
an
al
ys
is
1
In
fa
nt
su
pp
le
m
en
t
A
nt
hr
op
om
et
ri
cs
at
st
ar
to
f
su
pp
le
m
en
ta
tio
n2
A
ut
ho
rs
T
ri
al
na
m
e
C
ou
nt
ry
In
te
rv
en
tio
n
gr
ou
ps
M
at
er
na
ls
up
pl
em
en
t
A
ge
at
st
ar
t
D
ur
at
io
n
O
ut
co
m
e
as
ce
rt
ai
nm
en
td
es
cr
ip
tio
n
St
un
tin
g,
%
W
as
tin
g,
%
A
du
-A
fa
rw
ua
h
et
al
.(
14
)
G
ha
na
N
ut
ri
bu
tte
r
(2
0
g/
d;
10
8
kc
al
/d
)
Sp
ri
nk
le
s
po
w
de
r
N
ut
ri
ta
bs
(M
M
N
)
N
6
m
o
6
m
o
W
ee
kl
y
m
or
bi
di
ty
su
rv
ei
lla
nc
e
in
in
te
rv
en
tio
n
gr
ou
ps
5.
4
5.
4
Pa
ss
iv
e
co
nt
ro
l(
no
in
te
rv
en
tio
n)
A
du
-A
fa
rw
ua
h
et
al
.(
15
)
iL
iN
S-
D
Y
A
D
G
G
ha
na
L
N
S:
w
om
en
re
ce
iv
ed
SQ
-L
N
S
du
ri
ng
pr
eg
na
nc
y
an
d
fo
r
6
m
o
po
st
pa
rt
um
,c
hi
ld
re
ce
iv
ed
SQ
-L
N
S
(2
0
g/
d;
11
8
kc
al
/d
)
Y
6
m
o
12
m
o
W
ee
kl
y
m
or
bi
di
ty
su
rv
ei
lla
nc
e,
tr
ia
l
ho
tli
ne
fo
r
pa
rt
ic
ip
an
ts
—
—
M
M
N
:w
om
en
re
ce
iv
ed
M
M
N
du
ri
ng
pr
eg
na
nc
y
an
d
6
m
o
po
st
pa
rt
um
,n
o
ch
ild
su
pp
le
m
en
ta
tio
n
IF
A
:w
om
en
re
ce
iv
ed
IF
A
du
ri
ng
pr
eg
na
nc
y
an
d
pl
ac
eb
o
fo
r
6
m
o
po
st
pa
rt
um
,n
o
ch
ild
su
pp
le
m
en
ta
tio
n
A
sh
or
n
et
al
.(
16
)
iL
iN
S-
D
Y
A
D
M
M
al
aw
i
L
N
S:
w
om
en
re
ce
iv
ed
SQ
-L
N
S
du
ri
ng
pr
eg
na
nc
y
an
d
fo
r
6
m
o
po
st
pa
rt
um
,c
hi
ld
re
ce
iv
ed
SQ
-L
N
Ss
(2
0
g/
d;
11
8
kc
al
/d
)
Y
6
m
o
12
m
o
W
ee
kl
y
m
or
bi
di
ty
su
rv
ei
lla
nc
e,
tr
ia
l
co
nt
ac
tw
ith
lo
ca
lh
os
pi
ta
ls
—
—
M
M
N
:w
om
en
re
ce
iv
ed
M
M
N
du
ri
ng
pr
eg
na
nc
y
an
d
6
m
o
po
st
pa
rt
um
,n
o
ch
ild
su
pp
le
m
en
ta
tio
n
IF
A
:w
om
en
re
ce
iv
ed
IF
A
du
ri
ng
pr
eg
na
nc
y
an
d
pl
ac
eb
o
fo
r
6
m
o
po
st
pa
rt
um
,n
o
ch
ild
su
pp
le
m
en
ta
tio
n
B
ec
qu
ey
et
al
.(
17
)
PR
O
M
IS
B
ur
ki
na
Fa
so
SQ
-L
N
S
(2
0
g/
d;
11
8
kc
al
/d
)
A
ct
iv
e
co
nt
ro
l
N
6
m
o
12
m
o
M
on
th
ly
ho
m
e
vi
si
ts
by
re
se
ar
ch
st
af
f
—
—
B
is
im
w
a
et
al
.(
18
)
D
em
oc
ra
tic
R
ep
ub
lic
of
th
e
C
on
go
R
U
C
F:
L
N
S
(5
0
g/
d;
27
5
kc
al
/d
)
U
N
IM
IX
:M
M
N
-f
or
tifi
ed
co
rn
–s
oy
bl
en
d
(7
0
g/
d;
28
0
kc
al
/d
)
N
6
m
o
6
m
o
M
ed
ic
al
re
co
rd
s
or
ve
rb
al
au
to
ps
y
18
.6
5.
7
H
is
to
ri
ca
lc
on
tr
ol
C
hr
is
tia
n
et
al
.(
19
)
Ji
V
itA
-4
B
an
gl
ad
es
h
Pl
um
py
’D
oz
(2
3–
46
g/
d;
12
5–
25
0
kc
al
/d
)
N
6
m
o
12
m
o
Tw
ic
e-
w
ee
kl
y
m
or
bi
di
ty
su
rv
ei
lla
nc
e
25
.4
5.
8
C
hi
ck
pe
a
ba
se
d
L
N
S
(2
3–
46
kg
/d
;
12
5–
25
0
kc
al
/d
)
R
ic
e-
le
nt
il
L
N
S
(2
8–
56
g/
d;
12
5–
25
0
kc
al
/d
)
W
SB
++
:W
he
at
–s
oy
bl
en
d+
+
(3
2–
64
g/
d;
12
5–
25
0
kc
al
/d
)
A
ct
iv
e
co
nt
ro
l
D
ew
ey
et
al
.(
20
)
R
D
N
S
B
an
gl
ad
es
h
L
N
S-
L
N
S:
w
om
en
re
ce
iv
ed
SQ
-L
N
S
du
ri
ng
pr
eg
na
nc
y
an
d
fo
r
6
m
o
po
st
pa
rt
um
,c
hi
ld
re
ce
iv
ed
SQ
-L
N
S
(2
0
g/
d;
11
8
kc
al
/d
)
Y
6
m
o
18
m
o
H
om
e
vi
si
ts
ev
er
y
6
m
o
by
re
se
ar
ch
st
af
f
—
—
(C
on
ti
nu
ed
)
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/111/1/207/5613093 by Tam
pere university library user on 07 February 2020
212 Stewart et al.
T
A
B
L
E
1
(C
on
ti
nu
ed
)
In
fa
nt
su
pp
le
m
en
t
A
nt
hr
op
om
et
ri
cs
at
st
ar
to
f
su
pp
le
m
en
ta
tio
n2
A
ut
ho
rs
T
ri
al
na
m
e
C
ou
nt
ry
In
te
rv
en
tio
n
gr
ou
ps
M
at
er
na
ls
up
pl
em
en
t
A
ge
at
st
ar
t
D
ur
at
io
n
O
ut
co
m
e
as
ce
rt
ai
nm
en
td
es
cr
ip
tio
n
St
un
tin
g,
%
W
as
tin
g,
%
IF
A
-L
N
S:
w
om
en
re
ce
iv
ed
IF
A
du
ri
ng
pr
eg
na
nc
y
an
d
3
m
o
po
st
pa
rt
um
,c
hi
ld
re
ce
iv
ed
SQ
-L
N
S
(2
0
g/
d;
11
8
kc
al
/d
)
IF
A
-M
N
P:
w
om
en
re
ce
iv
ed
IF
A
du
ri
ng
pr
eg
na
nc
y
an
d
3
m
o
po
st
pa
rt
um
,c
hi
ld
re
ce
iv
ed
M
N
P
IF
A
-C
on
tr
ol
:w
om
en
re
ce
iv
ed
IF
A
du
ri
ng
pr
eg
na
nc
y
an
d
3
m
o
po
st
pa
rt
um
,n
o
ch
ild
su
pp
le
m
en
ta
tio
n
H
es
s
et
al
.(
21
)
iL
iN
S-
Z
in
c
B
ur
ki
na
Fa
so
L
N
S-
Z
n0
:L
N
S
(2
0
g/
d;
11
8
kc
al
)
co
nt
ai
ni
ng
0
m
g
Z
n/
d
an
d
pl
ac
eb
o
ta
bl
et
L
N
S-
Z
n5
:L
N
S
(2
0
g/
d;
11
8
kc
al
)
co
nt
ai
ni
ng
5
m
g
Z
n/
d
an
d
pl
ac
eb
o
ta
bl
et
N
9
m
o
9
m
o
W
ee
kl
y
m
or
bi
di
ty
su
rv
ei
lla
nc
e;
ca
re
gi
ve
r
in
te
rv
ie
w
at
en
dl
in
e
fo
r
pa
ss
iv
e
co
nt
ro
l
gr
ou
p
22
.4
16
.4
L
N
S-
Z
n1
0:
L
N
Ss
(2
0
g/
d;
11
8
kc
al
)
co
nt
ai
ni
ng
10
m
g
Z
n/
d
an
d
pl
ac
eb
o
ta
bl
et
L
N
S-
Ta
bZ
n5
(2
0
g/
d;
11
8
kc
al
)
co
nt
ai
ni
ng
0
m
g
Z
n/
d
an
d
Z
n
ta
bl
et
co
nt
ai
ni
ng
5
m
g
Z
n/
d
Pa
ss
iv
e
co
nt
ro
l(
no
in
te
rv
en
tio
n)
H
um
ph
re
y
et
al
.(
22
)
SH
IN
E
(H
IV
−)
3
Z
im
ba
bw
e
IY
C
F:
ch
ild
re
ce
iv
ed
SQ
-L
N
S
(2
0
g/
d;
11
8
kc
al
/d
)
N
6
m
o
12
m
o
M
on
th
ly
re
po
rt
s
fr
om
vi
lla
ge
he
al
th
w
or
ke
rs
—
—
W
A
SH
:f
am
ily
re
ce
iv
ed
ve
nt
ila
te
d
im
pr
ov
ed
pi
tl
at
ri
ne
,h
an
dw
as
hi
ng
st
at
io
ns
,s
oa
p,
ch
lo
ri
ne
,c
hi
ld
pl
ay
sp
ac
e
W
A
SH
an
d
IY
C
F:
ch
ild
re
ce
iv
ed
SQ
-L
N
S
(2
0
g/
d;
11
8
kc
al
/d
),
fa
m
ily
re
ce
iv
ed
ve
nt
ila
te
d
im
pr
ov
ed
pi
tl
at
ri
ne
,h
an
dw
as
hi
ng
st
at
io
ns
,
so
ap
,c
hl
or
in
e,
ch
ild
pl
ay
sp
ac
e
A
ct
iv
e
co
nt
ro
l(
st
an
da
rd
of
ca
re
)
H
uy
br
eg
ts
et
al
.(
23
)
PR
O
M
IS
M
al
i
SQ
-L
N
S
(2
0
g/
d;
11
8
kc
al
/d
)
A
ct
iv
e
co
nt
ro
l
N
6
m
o
18
m
o
M
on
th
ly
ho
m
e
vi
si
ts
by
re
se
ar
ch
st
af
f
—
—
Ia
nn
ot
ti
et
al
.(
24
)
H
ai
ti
N
ut
ri
bu
tte
r
(2
0
g/
d;
10
8
kc
al
/d
)
fo
r
6
m
o
N
6–
11
m
o
3–
6
m
o
M
on
th
ly
tr
ia
lv
is
it
9.
4
2.
2
N
ut
ri
bu
tte
r
(2
0
g/
d;
10
8
kc
al
/d
)
fo
r
3
m
o,
fo
llo
w
ed
by
st
an
da
rd
of
ca
re
A
ct
iv
e
co
nt
ro
l(
st
an
da
rd
of
ca
re
)
(C
on
ti
nu
ed
)
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/111/1/207/5613093 by Tam
pere university library user on 07 February 2020
Meta-analysis of effect of LNS on child mortality 213
T
A
B
L
E
1
(C
on
ti
nu
ed
)
In
fa
nt
su
pp
le
m
en
t
A
nt
hr
op
om
et
ri
cs
at
st
ar
to
f
su
pp
le
m
en
ta
tio
n2
A
ut
ho
rs
T
ri
al
na
m
e
C
ou
nt
ry
In
te
rv
en
tio
n
gr
ou
ps
M
at
er
na
ls
up
pl
em
en
t
A
ge
at
st
ar
t
D
ur
at
io
n
O
ut
co
m
e
as
ce
rt
ai
nm
en
td
es
cr
ip
tio
n
St
un
tin
g,
%
W
as
tin
g,
%
L
ub
y
et
al
.(
25
)
W
A
SH
-B
B
an
gl
ad
es
h
N
ut
ri
tio
n:
ch
ild
re
ce
iv
ed
L
N
S
(2
0
g/
d;
11
8
kc
al
/d
)
N
6
m
o
18
m
o
A
nn
ua
lc
ar
eg
iv
er
in
te
rv
ie
w
—
—
W
at
er
:f
am
ily
re
ce
iv
ed
ch
lo
ri
ne
fo
r
dr
in
ki
ng
w
at
er
Sa
ni
ta
tio
n:
fa
m
ily
re
ce
iv
ed
up
gr
ad
ed
la
tr
in
e,
sa
ni
-s
co
op
,a
nd
ch
ild
po
tty
H
an
dw
as
hi
ng
:f
am
ily
re
ce
iv
ed
ha
nd
w
as
hi
ng
st
at
io
ns
w
ith
so
ap
W
at
er
,s
an
ita
tio
n,
an
d
ha
nd
w
as
hi
ng
:
fa
m
ily
re
ce
iv
ed
al
lw
at
er
,
sa
ni
ta
tio
n,
an
d
hy
gi
en
e
in
te
rv
en
tio
ns
W
at
er
,s
an
ita
tio
n,
ha
nd
w
as
hi
ng
,a
nd
nu
tr
iti
on
:f
am
ily
re
ce
iv
ed
al
lw
at
er
,
sa
ni
ta
tio
n,
an
d
hy
gi
en
e
in
te
rv
en
tio
ns
,c
hi
ld
re
ce
iv
ed
L
N
S
(2
0
g/
d;
11
8
kc
al
/d
)
Pa
ss
iv
e
co
nt
ro
l(
no
in
te
rv
en
tio
n)
M
al
et
a
et
al
.(
26
)
iL
iN
S-
D
O
SE
M
al
aw
i
10
g/
d
m
ilk
L
N
S
(5
6
kc
al
/d
)
20
g/
d
m
ilk
L
N
S
(1
18
kc
al
/d
)
20
g/
d
no
-m
ilk
L
N
S
(m
al
to
de
xt
ri
n
su
bs
tit
ut
ed
)
(1
18
kc
al
/d
)
N
6
m
o
12
m
o
W
ee
kl
y
m
or
bi
di
ty
su
rv
ei
lla
nc
e,
tr
ia
l
co
nt
ac
tw
ith
lo
ca
lh
ea
lth
pr
ov
id
er
s
29
.3
—
40
g/
d
m
ilk
L
N
S
(2
36
kc
al
/d
)
40
g/
d
no
-m
ilk
L
N
S
(m
al
to
de
xt
ri
n
su
bs
tit
ut
ed
)
(2
36
kc
al
/d
)
A
ct
iv
e
co
nt
ro
l
M
an
ga
ni
et
al
.(
27
)
L
C
N
I-
5
M
al
aw
i
M
ilk
-L
N
S
(5
4
g/
d,
28
5
kc
al
/d
)
So
y-
L
N
S
(5
4
g/
d,
27
6
kc
al
/d
)
C
or
n–
so
y
bl
en
d
(7
1
g/
d,
28
4
kc
al
/d
)
N
6
m
o
12
m
o
W
ee
kl
y
m
or
bi
di
ty
su
rv
ei
lla
nc
e,
tr
ia
l
co
nt
ac
tw
ith
lo
ca
lh
ea
lth
cl
in
ic
s
36
.7
1.
7
A
ct
iv
e
co
nt
ro
l
M
at
ia
s
et
al
.(
28
)
Pe
ru
L
N
S:
N
ut
ri
bu
tte
r
(2
0
g/
d,
11
0
kc
al
/d
)
N
6
m
o
6
m
o
N
ot
re
po
rt
ed
10
.0
0.
8
M
N
P:
Sp
ri
nk
le
s
po
w
de
r
N
ul
le
ta
l.
(2
9)
W
A
SH
-B
K
en
ya
N
ut
ri
tio
n:
ch
ild
re
ce
iv
ed
L
N
S
(2
0
g/
d;
11
8
kc
al
/d
)
W
at
er
:f
am
ily
re
ce
iv
ed
ch
lo
ri
ne
fo
r
dr
in
ki
ng
w
at
er
Sa
ni
ta
tio
n:
fa
m
ily
re
ce
iv
ed
up
gr
ad
ed
la
tr
in
e,
sa
ni
-s
co
op
,a
nd
ch
ild
po
tty
N
6
m
o
18
m
o
M
on
th
ly
re
po
rt
s
fr
om
ch
ild
he
al
th
pr
om
ot
or
s;
an
nu
al
ca
re
gi
ve
r
in
te
rv
ie
w
in
pa
ss
iv
e
co
nt
ro
lg
ro
up
—
—
(C
on
ti
nu
ed
)
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/111/1/207/5613093 by Tam
pere university library user on 07 February 2020
214 Stewart et al.
T
A
B
L
E
1
(C
on
ti
nu
ed
)
In
fa
nt
su
pp
le
m
en
t
A
nt
hr
op
om
et
ri
cs
at
st
ar
to
f
su
pp
le
m
en
ta
tio
n2
A
ut
ho
rs
T
ri
al
na
m
e
C
ou
nt
ry
In
te
rv
en
tio
n
gr
ou
ps
M
at
er
na
ls
up
pl
em
en
t
A
ge
at
st
ar
t
D
ur
at
io
n
O
ut
co
m
e
as
ce
rt
ai
nm
en
td
es
cr
ip
tio
n
St
un
tin
g,
%
W
as
tin
g,
%
H
an
dw
as
hi
ng
:f
am
ily
re
ce
iv
ed
ha
nd
w
as
hi
ng
st
at
io
ns
w
ith
so
ap
W
at
er
,s
an
ita
tio
n,
an
d
ha
nd
w
as
hi
ng
:
fa
m
ily
re
ce
iv
ed
al
lw
at
er
,
sa
ni
ta
tio
n,
an
d
hy
gi
en
e
in
te
rv
en
tio
ns
W
at
er
,s
an
ita
tio
n,
ha
nd
w
as
hi
ng
,a
nd
nu
tr
iti
on
:f
am
ily
re
ce
iv
ed
al
lw
at
er
,
sa
ni
ta
tio
n,
an
d
hy
gi
en
e
in
te
rv
en
tio
ns
,c
hi
ld
re
ce
iv
ed
L
N
S
(2
0
g/
d;
11
8
kc
al
/d
)
Pa
ss
iv
e
co
nt
ro
l(
no
in
te
rv
en
tio
n)
A
ct
iv
e
co
nt
ro
l
Ph
uk
a
et
al
.(
30
)
M
al
aw
i
FS
-2
5:
m
ic
ro
nu
tr
ie
nt
-f
or
tifi
ed
sp
re
ad
(2
5
g/
d;
12
7
kc
al
/d
)
N
6
m
o
12
m
o
W
ee
kl
y
m
or
bi
di
ty
su
rv
ei
lla
nc
e
—
—
FS
-5
0:
m
ic
ro
nu
tr
ie
nt
-f
or
tifi
ed
sp
re
ad
(5
0
g/
d;
25
6
kc
al
/d
)
L
P:
L
ik
un
iP
ha
la
,
m
ic
ro
nu
tr
ie
nt
-f
or
tifi
ed
m
ai
ze
–s
oy
flo
ur
(7
1
g/
d;
28
2
kc
al
/d
)
Pr
en
de
rg
as
te
ta
l.
(3
1)
SH
IN
E
(H
IV
+)
3
Z
im
ba
bw
e
IY
C
F:
ch
ild
re
ce
iv
ed
SQ
-L
N
Ss
(2
0
g/
d;
11
8
kc
al
/d
)
N
6
m
o
12
m
o
M
on
th
ly
re
po
rt
s
fr
om
vi
lla
ge
he
al
th
w
or
ke
rs
—
—
W
A
SH
:f
am
ily
re
ce
iv
ed
ve
nt
ila
te
d
im
pr
ov
ed
pi
tl
at
ri
ne
,h
an
dw
as
hi
ng
st
at
io
ns
,s
oa
p,
ch
lo
ri
ne
,c
hi
ld
pl
ay
sp
ac
e
W
A
SH
an
d
IY
C
F:
ch
ild
re
ce
iv
ed
SQ
-L
N
S
(2
0
g/
d;
11
8
kc
al
/d
),
fa
m
ily
re
ce
iv
ed
ve
nt
ila
te
d
im
pr
ov
ed
pi
tl
at
ri
ne
,h
an
dw
as
hi
ng
st
at
io
ns
,
so
ap
,c
hl
or
in
e,
ch
ild
pl
ay
sp
ac
e
A
ct
iv
e
co
nt
ro
l(
st
an
da
rd
of
ca
re
)
Sm
ut
s
et
al
.(
32
)
So
ut
h
A
fr
ic
a
SQ
-L
N
S
(2
0
g/
d;
11
4
kc
al
/d
)
SQ
-L
N
S-
pl
us
:S
Q
-L
N
S
w
ith
ad
di
tio
na
lM
M
N
,D
H
A
,A
A
,
L
-l
ys
in
e,
an
d
ph
yt
as
e
(2
0
g/
d;
11
3
kc
al
/d
)
N
6
m
o
6
m
o
W
ee
kl
y
m
or
bi
di
ty
su
rv
ei
lla
nc
e
29
.5
1.
5
A
ct
iv
e
co
nt
ro
l
1
A
A
,a
ra
ch
id
on
ic
ac
id
;F
S,
fo
rt
ifi
ed
sp
re
ad
;I
FA
,i
ro
n–
fo
lic
ac
id
;I
Y
C
F,
in
fa
nt
an
d
yo
un
g
ch
ild
fe
ed
in
g;
L
N
S,
lip
id
-b
as
ed
nu
tr
ie
nt
su
pp
le
m
en
t;
L
P,
L
ik
un
iP
ha
la
;M
M
N
,m
ul
tip
le
m
ic
ro
nu
tr
ie
nt
s;
M
N
P,
m
ul
tip
le
m
ic
ro
nu
tr
ie
nt
po
w
de
r;
R
U
C
F,
re
ad
y-
to
-u
se
co
m
pl
em
en
ta
ry
fo
od
;S
Q
-L
N
S,
sm
al
l-
qu
an
tit
y
lip
id
-b
as
ed
nu
tr
ie
nt
su
pp
le
m
en
t;
W
A
SH
,w
at
er
,s
an
ita
tio
n,
an
d
hy
gi
en
e;
W
SB
,w
he
at
–s
oy
bl
en
d.
2
St
un
tin
g
is
de
fin
ed
as
le
ng
th
-f
or
-a
ge
z
sc
or
e
≤−
2
an
d
w
as
tin
g
is
de
fin
ed
as
w
ei
gh
t-
fo
r-
le
ng
th
z
sc
or
e
≤−
2.
T
ri
al
s
th
at
di
d
no
tr
ep
or
tb
as
el
in
e
st
un
tin
g
or
w
as
tin
g
pr
ev
al
en
ce
s
ar
e
in
di
ca
te
d
by
a
da
sh
ed
lin
e.
3
T
he
SH
IN
E
tr
ia
lw
as
a
si
ng
le
tr
ia
lp
ub
lis
he
d
in
2
re
po
rt
s
[H
um
ph
re
y
et
al
.(
22
)
an
d
Pr
en
de
rg
as
te
ta
l.
(3
1)
]
se
pa
ra
te
ly
by
H
IV
ex
po
su
re
st
at
us
of
th
e
in
fa
nt
.D
at
a
w
er
e
ex
tr
ac
te
d
se
pa
ra
te
ly
fr
om
th
e
2
re
po
rt
s.
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/111/1/207/5613093 by Tam
pere university library user on 07 February 2020
Meta-analysis of effect of LNS on child mortality 215
Trial
GHANA
PROMIS (Burkina Faso)
JiVitA-4
RDNS
iLiNS-Zinc
SHINE (HIV−)
PROMIS (Mali)
HAITI
WASH-B (Bangladesh)
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SOUTH AFRICA
Summary
Authors
Adu-Afarwuah et al. (14) 
Becquey et al. (17) 
Christian et al. (19) 
Dewey et al. (20) 
Hess et al. (21) 
Humphrey et al. (22) 
Huybregts et al. (23) 
Iannotti et al. (24) 
Luby et al. (25) 
Maleta et al. (26) 
Mangani et al. (27) 
Null et al. (29) 
Prendergast et al. (31) 
Smuts et al. (32) 
I ² = 23, s ² = 0.04
Country
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Bangladesh
Burkina Faso
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Bangladesh
Malawi
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South Africa
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 (g/d)
20
20
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20
20
20
20
20
20
10–40
54
20
20
20
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n
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815
2435
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1247
1612
422
1705
350
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16,062 218
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0
11
17
2
33
20
16
1
8
63
9
29
6
3
Control
n
97
1046
1438
864
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567
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3758
320
209
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348
250
17,989
Deaths
0
5
12
9
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21
0
34
15
8
133
5
2
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RR (95% CI)
—
2.32 (0.81, 6.66)
0.64 (0.31, 1.35)
0.24 (0.05, 1.09)
0.43 (0.25, 0.71)
0.77 (0.43, 1.38)
0.76 (0.40, 1.45)
—
0.71 (0.33, 1.53)
0.83 (0.48, 1.45)
0.56 (0.22, 1.42)
0.80 (0.54, 1.19)
1.19 (0.37, 3.87)
0.75 (0.13, 4.46)
0.73 (0.59, 0.89)
Weight
0.01
0.06
0.14
0.05
0.09
0.11
0.03
0.01
0.15
0.06
0.02
0.23
0.02
0.02
0.08 0.12 0.18 0.25 0.35 0.50 0.71 1.00 1.40 2.00 3.00 4.00
RR of mortality
                             Favors LNS    Favors control
FIGURE2 Effect of LNSwith or without other interventions on all-causemortality in children 6–24mo of age. The SHINE trial presented results in separate
reports for children born to HIV+ and HIV− mothers and these have therefore been listed as 2 rows in this figure. LNS, lipid-based nutrient supplement.
arms containing LNS and compared thosewith armswithout LNS
with a goal of maximizing the sample size and power to detect
a difference. In a more restrictive sensitivity analysis in which
we excluded passive control arms from the analysis and only
contrasted LNS groups with comparison groups that contained all
the same components without LNS, the estimated risk reduction
was reduced to 18% and was no longer statistically significant.
There are a few notable differences in comparing the primary
analysis with the latter sensitivity analysis. First, the sensitivity
analysis excluded the iLiNS-Zinc trial in Burkina Faso (21)
and the Ghana trial (14) completely, which may explain some
of the attenuation in effect in this sensitivity analysis. The
iLiNS-Zinc trial was the only trial that independently had a
significant mortality risk reduction (RR: 0.43; 95% CI: 0.25,
0.71) and it also provided surveillance and treatment of diarrhea
and malaria in the intervention groups but not in the passive
control group. The second difference was in the contrasts for
the 3 WASH + Nutrition trials (WASH Benefits Bangladesh
and Kenya and SHINE in Zimbabwe). To isolate the effects of
LNS, this sensitivity analysis compared the LNS arm with the
Active Control arm in WASH Benefits Kenya and SHINE and
the LNS + WASH arm with the WASH arm in all 3 trials. It also
excluded the independent water, sanitation, and handwashing
arms from the 2 WASH Benefits trials. The difference in the
point estimate in this sensitivity analysis compared with the
primary analysis did not appear to be due to a protective effect
of the WASH interventions. There was no risk reduction in
those arms in either of the WASH Benefits trials. Although
the combined LNS + WASH arm had a nonsignificantly lower
mortality rate than the LNS arm in Kenya, this was not the
case in the other 2 trials. The LNS + WASH arm in WASH
Benefits Bangladesh had a higher mortality rate than the LNS
group. Similarly, in the SHINE trial, the LNS + WASH group
had a higher mortality rate than the LNS group. Lastly, this
sensitivity analysis included a smaller sample size (23,373
compared with 34,051 in the primary analysis) and fewer deaths
(349 compared with 512), which reduced the power to detect
differences.
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RR of mortality
                       Favors LNS    Favors control
FIGURE 3 Sensitivity analysis including arms with combined maternal + child supplementation. The SHINE trial presented results in separate reports
for children born to HIV+ and HIV− mothers and these have therefore been listed as 2 rows in this figure. LNS, lipid-based nutrient supplement.
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GHANA
PROMIS (Burkina Faso)
JiVitA-4
RDNS
iLiNS-Zinc
SHINE (HIV−)
PROMIS (Mali)
HAITI
WASH-B (Bangladesh)
iLiNS-DOSE
LCNI-5
WASH-B (Kenya)
SHINE (HIV+)
Summary
Authors
Adu-Afarwuah et al. (14) 
Becquey et al. (17) 
Christian et al. (19) 
Dewey et al. (20) 
Hess et al. (21) 
Humphrey et al. (22) 
Huybregts et al. (23) 
Iannotti et al. (24) 
Luby et al. (25) 
Maleta et al. (26) 
Mangani et al. (27) 
Null et al. (29) 
Prendergast et al. (31) 
I ² = 29, s² = 0.06
Country
Ghana
Burkina Faso
Bangladesh
Bangladesh
Burkina Faso
Zimbabwe
Mali
Haiti
Bangladesh
Malawi
Malawi
Kenya
Zimbabwe
Quantity
 (g/d)
20
20
23–56
20
20
20
20
20
20
10–40
54
20
20
LNS
n
103
991
1492
815
2435
1955
565
202
1247
965
212
1705
350
13,037
Deaths
0
11
9
2
33
20
16
1
8
37
4
29
6
176
Control
n
97
1046
1438
864
785
1881
567
191
3758
320
209
6235
348
17,739
Deaths
0
5
12
9
25
25
21
0
34
15
8
133
5
292
RR (95% CI)
—
2.32 (0.81, 6.66)
0.72 (0.31, 1.71)
0.24 (0.05, 1.09)
0.43 (0.25, 0.71)
0.77 (0.43, 1.38)
0.76 (0.40, 1.45)
—
0.71 (0.33, 1.53)
0.82 (0.46, 1.47)
0.49 (0.15, 1.61)
0.80 (0.54, 1.19)
1.19 (0.37, 3.87)
0.73 (0.58, 0.91)
Weight
0.01
0.07
0.10
0.05
0.10
0.12
0.04
0.01
0.16
0.04
0.01
0.26
0.02
0.08 0.12 0.18 0.25 0.35 0.50 0.71 1.00 1.40 2.00 3.00 4.00
RR of mortality
                             Favors LNS    Favors control
FIGURE 4 Sensitivity analysis excluding arms that were not peanut- andmilk-based LNS. The SHINE trial presented results in separate reports for children
born to HIV+ and HIV− mothers and these have therefore been listed as 2 rows in this figure. LNS, lipid-based nutrient supplement.
We cannot draw conclusions about the comparison of LNS
with alternative products. The sample size in this analysis was
small (n = 8681 children and n = 72 deaths) and there was a
lot of variation in the comparison products, which likely partly
explains the large degree of heterogeneity in the results.
Our estimated effect differs from the RR of 0.93 (95% CI:
0.63, 1.37) recently reported by Das et al. (7) in a number of
ways. First, our analysis includes 41,280 children, whereas their
analysis included 3321 children. Second, our analysis is restricted
to children who were eligible to receive LNS. In the Das et al.
review, 2 of the trials were maternal + child LNS trials (15, 16)
and mortality outcomes were reported from birth. Thus, some
of the deaths occurred before the age of 6 mo when children
would have been eligible to first receive LNS directly. Third, in
our primary analysis, we combined all groups who received LNS
and compared them with all groups who had not received LNS,
enabling us to draw more information from the trials.
Our estimated effect size is similar to that reported for the
effect of maternal LNS on neonatal mortality (RR: 0.72; 95%
CI: 0.47, 1.10), although this was not statistically significant (8).
Nevertheless, the consistency in the direction and magnitude of
the effect is notable. Additional trials have been completed since
the publication of that review (33), offering additional statistical
power to test this hypothesis in the future.
We can only speculate on the potential mechanisms that
may explain the observed effect. One possibility is that there
was a protective effect through the prevention of wasting. In
the Das et al. (7) review, there was an 18% reduction in
the prevalence of wasting (RR: 0.82; 95% CI: 0.74, 0.91).
Similarly in the PROMIS Mali trial, which was not included
in the Das et al. review, there was a risk reduction of 29% in
the incidence of acute malnutrition (95% CI: 8%, 46%) (23).
Moderate wasting has been associated with a 3.4-fold increased
risk ofmortality, whereas severe wasting has been associatedwith
>11-fold increased risk (3). Undernutrition is also associated
with increased susceptibility to and severity of infections. None
of the trials reported cause-specific mortality and, although many
reported morbidity outcomes, the results have been inconsistent.
Trial
PROMIS (Burkina Faso)
JiVitA-4
RDNS
SHINE (HIV−)
SHINE (HIV−) [vs. WSH]
PROMIS (Mali)
HAITI
WASH-B (Bangladesh) [vs. WSH]
iLiNS-DOSE
LCNI-5
WASH-B (Kenya)
WASH-B (Kenya) [vs. WSH]
SHINE (HIV+)
SHINE (HIV+) [vs. WSH]
SOUTH AFRICA
Summary
Authors
Becquey et al. (17) 
Christian et al. (19) 
Dewey et al. (20) 
Humphrey et al. (22) 
Humphrey et al. (22) 
Huybregts et al. (23) 
Iannotti et al. (24) 
Luby et al. (25) 
Maleta et al. (26) 
Mangani et al. (27) 
Null et al. (29) 
Null et al. (29) 
Prendergast et al. (31) 
Prendergast et al. (31) 
Smuts et al. (32) 
I ² = 33, s² = 0.10
Country
Burkina Faso
Bangladesh
Bangladesh
Zimbabwe
Zimbabwe
Mali
Haiti
Bangladesh
Malawi
Malawi
Kenya
Kenya
Zimbabwe
Zimbabwe
South Africa
Quantity
 (g/d)
20
23–56
20
20
20
20
20
20
10–40
54
20
20
20
20
20
LNS
n
991
3160
815
928
1027
565
202
623
1612
422
823
882
154
196
500
12,900
Deaths
11
17
2
7
13
16
1
7
63
9
20
9
3
3
3
184
Control
n
1046
1438
864
924
957
567
191
636
320
209
1852
871
156
192
250
10,473
Deaths
5
12
9
14
11
21
0
12
15
8
29
22
4
1
2
165
RR (95% CI)
2.32 (0.81,  6.66)
0.64 (0.31,  1.35)
0.24 (0.05,  1.09)
0.50 (0.20,  1.23)
1.10 (0.50,  2.45)
0.76 (0.40,  1.45)
—
0.60 (0.24,  1.50)
0.83 (0.48,  1.45)
0.56 (0.22,  1.42)
1.55 (0.88,  2.73)
0.40 (0.19,  0.87)
0.76 (0.17,  3.34)
2.94 (0.31, 28.01)
0.75 (0.13,  4.46)
0.82 (0.61,  1.10)
Weight
0.09
0.20
0.07
0.08
0.08
0.05
0.02
0.05
0.08
0.03
0.11
0.08
0.01
0.02
0.03
0.08 0.12 0.18 0.25 0.35 0.50 0.71 1.00 1.40 2.00 3.00 4.00
RR of mortality
                             Favors LNS    Favors control
FIGURE 5 Sensitivity analysis excluding passive control arms and comparing LNSmulticomponent arms with reference groups with the same components
without LNS. The SHINE trial presented results in separate reports for children born to HIV+ and HIV−mothers and these have therefore been listed as 2 rows
in this figure. In the WASH + Nutrition trials, we have included up to 2 sets of contrasts for each trial: LNS compared with active control and LNS + WASH
compared with WASH arms. LNS, lipid-based nutrient supplement; WASH, water, sanitation, and hygiene.
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One trial in Bangladesh (25) reported a reduction in diarrhea,
whereas 6 trials (19, 22, 29, 31, 34, 35) did not find a difference
and 2 trials (32, 36) reported an increased risk. Five trials
(19, 22, 24, 34, 35) reported no effects on pneumonia or
respiratory symptoms, and 2 trials (32, 36) reported a reduction
in respiratory symptoms. Five trials (24, 29, 32, 34, 36) reported
no effects on malaria or fever, whereas 1 trial (27) reported
an increase in malaria-related health center visits. Beyond the
common symptoms of infection, other complications of acute
undernutrition that may increase the risk of mortality include
hypothermia, fluid and electrolyte imbalances, hypoglycemia,
and cardiac and respiratory dysfunction (37).
In addition to the biological mechanisms, the intervention may
have improved other aspects of caregiving behaviors. Most trials
provided counseling by a community health worker or study
staff on IYCF or other caregiving messages together with LNS
supplementation. It is possible that frequent contact with a health
worker could lead to greater care and attention to the child. Most
trials included an active control group, in which there was a
comparable contact with a health worker. However, there were a
few trials with a passive control group. Indeed, when these trials
were removed from the analysis, the point estimate shifted toward
the null, yet the RR of 0.82 remained of a magnitude of public
health importance.
There are some important limitations with this analysis. We
lack detailed information on cause-specific mortality, data which
could provide insight into possible mechanisms of effect. In
addition, the variation in trial design, particularly with respect
to passive control groups and multicomponent interventions,
complicates the interpretation of results. In the trials with passive
controls, there was no contact with participants in the control
group yet frequent contact in the intervention groups. The
outcome ascertainment may have differed between the arms:
retrospective in the control compared with prospective in the
intervention groups, which could lead to a biased effect estimate.
We would expect this to be minimal for an outcome such as
mortality. Yet, active contact with participants could have carried
a survival benefit independent of LNS through enhanced care.
More trials with a direct comparison of an intervention package
with and without LNS are needed.
There are many strengths to this analysis. The sample size
was adequate to detect a mortality difference of public health
importance. The analytic sample was specific to the period of
LNS supplementation, which was achieved by obtaining data
from researchers when not available in the publications. All
analyses were prespecified and publicly posted. We focused on
a single study endpoint and the findings from the sensitivity
analyses were generally comparable with that of the primary
analysis, suggesting that the results were not due to chance.
Overall, there was a generally low degree of heterogeneity across
trials in all analyses, as suggested by the I2 statistics <40%
(10). There also was a low risk of bias across the trials on most
criteria, with the exception of blinding participants. Nevertheless,
mortality is an objective outcome less affected by respondent or
interviewer biases. Selective outcome reporting and publication
biases were minimized by extracting the data directly from trial
flow diagrams and contacting investigators.
Our analyses suggest that the provision of small- and medium-
quantity LNS for the prevention of malnutrition likely is
associated with a reduction in the risk of all-cause mortality
among children aged 6–24 mo. The trials were conducted in
multiple countries in different geographic regions and so these
results are likely broadly generalizable to many low- and middle-
income country contexts. More research is needed on cause-
specific mortality to provide a greater understanding of the causal
mechanisms and to incorporate into models such as the Lives
Saved Tool (38). Nevertheless, the present analysis provides
evidence that reduction in mortality is a likely additional benefit
of LNS beyond improvements in growth andmicronutrient status.
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